comprising a combination of Valsartan or a
pharmaceutically acceptable salt thereof and Sacubitril or a
pharmaceutically acceptable salt and a pharmaceutically acceptable carrier
or more ... specifically a pharmaceutical composition comprising combination
of Sacubitril +Valsartan as a sodium salt complex or in any other form
CS(COMM) 62/2019 & connected
suit patent, it is asserted, consists of a combination of
Valsartan and Sacubitril, which is novel and inventive in nature, and
treats cardiovascular diseases ... administration of a
vasodilator or NEP (Neutral Endopeptidase) inhibitors alone.
Sacubitril is a NEP and Valsartan is a vasodilator. The ―unexpected
and surprising synergistic antihypertensive
inventive pharmaceutical composition comprising of
Valsartan (or a pharmaceutically acceptable salt thereof),
Sacubitril (or a pharmaceutically acceptable salt thereof)
and a pharmaceutically acceptable carrier ... appellant/defendant had
2
obtained manufacturing approval for a formulation of
Sacubitril/Valsartan tablet from Central Drugs Standard
Control Organization (CDSCO) which constitutes an
imminent
pharmaceutical composition consisting
of Valsartan or a pharmaceutically acceptable salt thereof, and Sacubitril or
a pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier ... composition comprising
combination of valsartan or a pharmaceutically
acceptable salt thereof and sacubitril or a
pharmaceutically acceptable salt, and a
pharmaceutically acceptable carrier or more
caused to import or caused to trade the
pharmaceutical preparation namely SACUBITRIL +
VALSARTAN, in any manner, either directly or
indirectly.
5) I say that ... 1325 from FDA, India
to export the pharmaceutical preparation namely
'SACUBITRIL + VALSARTAN'.
7) It is stated that the defendant
that
the suit patent relates to a pharmaceutical combination comprising of
Valsartan + Sacubitril which have different mechanism of action together in
combination. It is pleaded ... sell and offer for sale the pharmaceutical
composition comprising combination of Valsartan + Sacubitril. The plaintiff
developed the drug formulation and marketed it under the trade
plaintiffs claim that they are producing a pharmaceutical
composition consisting of sacubitril and valsartan. The product is sold under
the brand name "Vymada ... Directorate General of Health Services for
manufacturing a Fixed-Dose combination of sacubitril and valsartan which,
according to them, infringes the suit patent
manufacturing and marketing a product
consisting of a combination of Valsartan and Sacubitril. The merits of
that suit need not detain us. Natco, however, contends
pharmaceutically acceptable carrier or more
specifically a pharmaceutical composition comprising combination of
sacubitril + valsartan as sodium salt complex/compound or in any other
form ... composition comprising combination of valsartan
or a pharmaceutically acceptable salt thereof and sacubitril or a
pharmaceutically acceptable salt, and a pharmaceutically
acceptable carrier or more
composition comprising a combination of
Valsartan or a pharmaceutically acceptable salt, and
Sacubitril or a pharmaceutically acceptable salt and a
pharmaceutically acceptable carrier or more ... specifically a
pharmaceutical composition comprising combination of
Sacubitril +Valsartan as a sodium salt complex or in any
Signature Not Verified
Digitally Signed By:VIJAYA
LAKSHMI
